Suppliers and packagers for emtriva

emtriva

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead	EMTRIVA	emtricitabine	CAPSULE;ORAL	021500	NDA	Gilead Sciences, Inc.	61958-0601-1	30 CAPSULE in 1 BOTTLE, PLASTIC (61958-0601-1)	2003-07-02
Gilead	EMTRIVA	emtricitabine	SOLUTION;ORAL	021896	NDA	Gilead Sciences, Inc.	61958-0602-1	1 BOTTLE, DISPENSING in 1 CARTON (61958-0602-1) / 170 mL in 1 BOTTLE, DISPENSING	2005-09-28

Suppliers for the Pharmaceutical Drug: Emtriva

Last updated: August 1, 2025

Introduction

Emtriva, the brand name for emtricitabine, is a crucial antiretroviral medication primarily used in the management of HIV-1 infection. As part of combination therapy, it helps suppress viral replication, improving patient outcomes and reducing disease progression. The pharmaceutical supply chain for Emtriva is integral to ensuring consistent access globally, necessitating an understanding of its key suppliers, manufacturing sources, and distribution channels.

Manufacturers and Original Suppliers

Emtriva was initially developed by Gilead Sciences, a biopharmaceutical company renowned for its portfolio of antiviral drugs. Gilead holds the original patent rights and has been the primary supplier of Emtriva since its FDA approval in 2006. The active pharmaceutical ingredient (API) and finished formulations are produced in Gilead’s manufacturing facilities, predominantly in the United States and other regulated jurisdictions. These facilities comply with Good Manufacturing Practices (GMP), ensuring product safety and efficacy.

Contract Manufacturing and Licensing Agreements

Given the high demand for antiretroviral drugs globally, Gilead has entered into licensing agreements with generic manufacturers, especially in low- and middle-income countries (LMICs). This strategy aims to improve access by allowing local production while maintaining quality standards. Approved generic manufacturers include:

• Cipla Ltd. (India): Licensed from Gilead, Cipla produces generic emtricitabine, often combined with other antiretrovirals. Their production facilities adhere to stringent GMP standards to ensure bioequivalence and quality.

• Hetero Drugs Ltd. (India): Another licensed producer manufacturing emtricitabine under Gilead’s licensing agreements, focusing on affordability and supply in resource-limited settings.

• Aurobindo Pharma Ltd. (India): Engaged in licensed production of emtricitabine for global markets, contributing extensively to generic supply chains.

These partnerships exemplify strategic licensing to expand access, especially in sub-Saharan Africa and Asia, where local manufacturing bridges supply gaps.

Global Distribution and Supply Chain Dynamics

Once manufactured, Emtriva and its generics are distributed via a network involving Gilead’s distribution channels, authorized wholesalers, and regional distributors. Gilead maintains strict supply chain controls to prevent counterfeiting and ensure product integrity. The global supply relies heavily on the following factors:

• Regulatory approvals: Ensuring compliance with health authorities such as the FDA, EMA, and local regulatory agencies dictates the ability to distribute Emtriva.

• Manufacturing capacity: Gilead’s investment in manufacturing expansion addresses global demand surges, particularly in response to HIV/AIDS treatment programs.

• Pricing and licensing policies: Gilead’s voluntary licensing (VL) program facilitates access to generics, especially in LMICs, reducing costs and increasing availability. These licensing agreements are key to understanding supply sources.

• Supply chain challenges: Periodic shortages can occur due to manufacturing delays, regulatory hurdles, or geopolitical factors, affecting supply stability.

Emerging Suppliers and Market Trends

In recent years, the landscape has evolved with increased participation of generic producers in emerging markets. Notable trends include:

• Bioequivalent Generics: Indian manufacturers, under strict regulatory oversight, produce bioequivalent versions of emtricitabine, expanding accessible supply.

• Regional Manufacturing Hubs: Countries like South Africa and Brazil are investing in local production capabilities, aiming to reduce dependency on imported drugs and ensure supply resilience.

Impact of Patent Expirations and Regulatory Policies

The expiration of patent protections in certain jurisdictions has facilitated the entry of multiple generic suppliers, diversifying the supply ecosystem. This development enhances supply security, reduces costs, and promotes competition. Gilead’s licensing model has been pivotal in this shift, often stipulating quality assurance standards for licensed manufacturers.

Conclusion

The supply landscape for Emtriva is characterized by a core of Gilead Sciences as the original producer, complemented by a broad network of licensed generic manufacturers in India and other emerging markets. Strategic licensing, regional manufacturing capacity, and regulatory oversight underpin the global supply chain. As HIV treatment paradigms evolve and demand increases, sustainable supply hinges on partnerships with competent manufacturers, regulatory harmonization, and proactive supply chain management.

---

Key Takeaways

• Gilead Sciences remains the primary supplier of Emtriva, overseeing initial manufacturing, with licensed generic producers expanding global availability.
• Indian pharmaceutical companies like Cipla, Hetero, and Aurobindo dominate licensed production, crucial to supply in resource-limited settings.
• Licensing agreements facilitate cost-effective access, especially in LMICs, bolstering global HIV treatment programs.
• Supply chain resilience depends on manufacturing capacity, regulatory compliance, and proactive management of geopolitical and economic factors.
• Regional manufacturing initiatives in Africa and Latin America are emerging to enhance supply security and reduce reliance on imports.

---

FAQs

1. Who are the main suppliers of Emtriva globally?
The primary supplier is Gilead Sciences, which manufactures the original product. Licensed generic manufacturers, primarily based in India, such as Cipla, Hetero, and Aurobindo, also supply Emtriva through licensing agreements.

2. How does licensing affect the supply of Emtriva in developing countries?
Licensing allows generic manufacturers to produce bioequivalent versions, increasing supply, reducing prices, and improving access in low- and middle-income countries.

3. Are there regional differences in Emtriva supply sources?
Yes. While Gilead is the primary supplier globally, local production in emerging markets, such as India and South Africa, supplements supply, often driven by licensing agreements and regional manufacturing initiatives.

4. What challenges threaten the supply stability of Emtriva?
Manufacturing delays, regulatory hurdles, intellectual property disputes, and geopolitical issues can cause shortages or disruptions in supply.

5. Will patent expirations influence future suppliers of Emtriva?
Yes. Patent expiration in certain regions has opened opportunities for additional generic suppliers, diversifying the supply chain and potentially lowering costs.

---

References

[1] Gilead Sciences. Emtriva (emtricitabine) Drug Profile. Gilead.
[2] World Health Organization. Global Antiretroviral Drug Supply Chain Insights. WHO Report 2022.
[3] Cipla Ltd. Official Website. Product Portfolio.
[4] Hetero Drugs Ltd. Licensing and Production Details. Hetero.
[5] Aurobindo Pharma. Corporate Overview and Generic Drug Production. Aurobindo.